TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24889937
Drug: Combination budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination budesonide/formoterol inhaler as maintenance and reliever therapy ('SMART') regimen
Study: 23110481
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional carbon dioxide laser treatment at pulse durations of 500, 1,000, 1,500, and 1,800 μs.
Study: 20488910
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg metformin three times a day for 4.3 years
Study: 9280994
Drug: Propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol in continuous infusion with O2 and air (group III)
Study: 1587065
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg losartan
Study: 25537204
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for RPE65-LCA
Study: 18544723
Drug: H. perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. perforatum (St John's wort) 300 mg standardized to 0.3% hypericin, taken 3 times daily for 8 weeks
Study: 18544723
Drug: Placebo, matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matched to H. perforatum, taken 3 times daily for 8 weeks
Study: 15809508
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (750-3,000 mg/day)
Study: 15809508
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1,500-9,000 mg/day)
Study: 10781212
Drug: Pentoxifylline 800
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 800 mg three times a day
Study: 9114906
Drug: Budesonide inhaled
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide inhaled from a Turbuhaler (1 mg)
Study: 27501616
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 30 mL (Gr. B)
Study: 27501616
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of 0.5% bupivacaine 20 mL and 2% lidocaine 10 mL (Gr. BL)
Study: 24671522
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin 100 mg od
Study: 22571201
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg per day, range 5 to 15)
Study: 8770849
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg r‐ProUK over 90 minutes
Study: 8770849
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg r‐ProUK over 60 minutes (primed with recombinant urokinase)
Study: 8770849
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg r‐ProUK over 90 minutes (primed with recombinant urokinase)
Study: 2202709
Drug: Metronidazole 800
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 800 mg
Study: 6999618
Drug: Thiamphenicol (TAP)
Normalized name: thiamphenicol
DrugBank: Thiamphenicol (DB08621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol (TAP) 1.5 g daily for 14 days
Study: 6999618
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 0.48 g TMP and 2.4 g SMZ daily for 14 days
Study: 21394639
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 600 mg PO
Study: 17210881
Drug: Alteplase plus
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase plus heparin sodium
Study: 11589932
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (perindopril plus indapamide)
Study: 12953850
Drug: Single-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug therapy (perindopril alone)
Study: 9751239
Drug: Niaspan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan 1.5 g at bedtime
Study: 9751239
Drug: Plain niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain niacin 1.5 g/d after 8 weeks
Study: 17534379
Drug: Physostigmine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (1.0 mg/h)
Study: 11403977
Drug: Buserelin treatment
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin treatment
Study: 29801011
Drug: Saline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (100 mL)
Study: 29801011
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of gemcitabine (2 g in 100 mL of saline)
Study: 27166360
Drug: Panobinostat 30
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat 30 mg orally 3 times weekly
Study: 12432968
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg alone
Study: 12432968
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg plus nizatidine 300 mg
Study: 1849442
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (high-dose epirubicin)
Study: 26891418
Drug: Early on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early on-treatment HCV RNA
Study: 24950920
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume with PEEP (tidal volume = 6 mL/kg, rate = 18/minute, PEEP = 5 cm H(2)O)
Study: 24950920
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (tidal volume = 10 mL/kg, rate = 12/minute, PEEP = 0 cm H(2)O)
Study: 17991646
Drug: Low-glucose solutions
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-glucose solutions
Study: 17991646
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and BG AUCs
Study: 14733451
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (7.5 mg)
Study: 15231557
Drug: Intramuscular lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lorazepam (4 mg)
Study: 10921707
Drug: Heparin-bonded circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded circuits
Study: 11334193
Drug: Non-heparin-bonded circuits
Normalized name: SKIN BOND NON-FLAMMABLE CEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-bonded circuits
Study: 1277740
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of methylglucamine iodipamide
Study: 1277740
Drug: Both methods
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both methods (infusion and single bolus)
Study: 25636814
Drug: WBVT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBVT + L-citrulline
Study: 25636814
Drug: All interventions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All interventions (WBVT, L-citrulline, WBVT + L-citrulline)
Study: 16835031
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (gentle rubbing, stroking, passive movements of the limbs) performed by professionals until the infant is 8 months old
Study: 15577227
Drug: Ninjin-to (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ninjin-to (6.0 g, single oral administration)
Study: 3087617
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) at 60 mg/m2, Ifosfamide (IFF) at 7500 mg/m2, Dacarbazine (DTIC) at 900 mg/m2 by continuous infusion over 72 hours
Study: 3087617
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) by continuous infusion
Study: 31943737
Drug: Treatment assignment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assignment with a biomarker measurement
Study: 31943737
Drug: Time-dependent logistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-dependent logistic model for treatment response
Study: 29546305
Drug: Daily nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nutritional dose of antioxidant supplement (120 mg vitamin C, 6 mg β-carotene, 30 mg vitamin E, 100 μg Se, 20 mg Zn)
Study: 21438929
Drug: Baseline CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline CSF L‐PGDS
Study: 21438929
Drug: Change of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change of CSF L‐PGDS after weight loss
Study: 17967218
Drug: Aquacultured salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquacultured salmon (250 g daily for 4 weeks providing 5 mug AST/g salmon flesh)
Study: 17967218
Drug: Wild salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild salmon (250 g daily for 4 weeks providing 5 mug AST/g salmon flesh)
Study: 28948645
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate (50 mg/d)
Study: 23098480
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about cervical cancer and HPV vaccine
Study: 20335115
Drug: Basal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal treatment (Control group)
Study: 2851179
Drug: Etoposide (single-agent)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (single-agent)
Study: 16965639
Drug: Behavioral addiction
Normalized name: DRUGS USED IN ADDICTIVE DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral addiction treatment with systematic reinforcement for goal attainment
Study: 16965639
Drug: Behavioral addiction
Normalized name: DRUGS USED IN ADDICTIVE DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral addiction treatment
Study: 14633804
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cinnamon daily
Study: 14633804
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of cinnamon daily
Study: 14633804
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of cinnamon daily
Study: 10627108
Drug: Aftercare treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aftercare treatment
Study: 11255446
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/d
Study: 19055286
Drug: Routine massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine massage therapy in Tuina Science (Control)
Study: 16649966
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (5 mg of folic acid)
Study: 12839261
Drug: 0.01% estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% estradiol cream
Study: 12839261
Drug: 15% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% glycolic acid cream
Study: 12839261
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.01% estradiol and 15% glycolic acid creams
Study: 6720281
Drug: Indomethacin solution
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin solution (1% watery solution, 1 drop, 4 times a day for 2 weeks)
Study: 6720281
Drug: Indomethacin solution
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin solution (local application during the first week post-surgery)
Study: 31582360
Drug: High-titre anti-influenza
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titre anti-influenza plasma (haemagglutination inhibition antibody titre ≥1:80)
Study: 28811653
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of daily energy consumed in the morning (BF group)
Study: 28811653
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of daily energy consumed in the evening (D group)
Study: 26742068
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein (12 g) + normal fiber (2 g)
Study: 26742068
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (25 g) + high fiber (8 g)
Study: 24958250
Drug: Electronic cigarette
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic cigarette (medium-strength nicotine concentration 11 mg/ml for 7 minutes)
Study: 20539854
Drug: Cardiovascular risk
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular risk management package including education about risk factors and treatment with hydrochlorothiazide at 4 months for medium-risk patients.
Study: 12120884
Drug: IFN‐alpha2a 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha2a 9 million units 3x week for 6 months with HBV vaccine 20 microg given on 0, 1 and 2 months
Study: 2669648
Drug: PGI2‐A (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGI2‐A (300 micrograms/L)
Study: 1033056
Drug: Tablets taken
Normalized name: levonorgestrel Oral Tablet [Take Action]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken half-an-hour before breakfast
Study: 1033056
Drug: Tablets taken
Normalized name: levonorgestrel Oral Tablet [Take Action]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken one hour before breakfast
Study: 1287618
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF (375 mg twice daily)
Study: 1287618
Drug: Cefaclor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (250 mg three times daily)
Study: 6700601
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without lithium carbonate
Study: 30548118
Drug: M. officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. officinalis capsules (700 mg/d)
Study: 29798118
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment and psychological intervention
Study: 29798118
Drug: Pure drug
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure drug therapy (Control)
Study: 25087210
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training, device training and home treatment (experimental group)
Study: 16809572
Drug: Geranylgeranyl transferase
Normalized name: geranylgeranylacetone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geranylgeranyl transferase inhibitor, toxin B, C3 exoenzyme, Y‐27632
Study: 3966742
Drug: Continuous oxygen
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oxygen therapy
Study: 8011570
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg and slow release nifedipine 20 mg twice a day
Study: 2887542
Drug: Beta-adrenergic blockade
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockade (celiprolol, 600 mg)
Study: 2887542
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockade (diltiazem, 30 or 60 mg four times daily)
Study: 29599391
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum injection followed by limited fasciectomy in non-responsive cases
Study: 22000583
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alcohol (1-2 mL)
Study: 18471252
Drug: Eicosapentaenoic/docosahexaenoic PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eicosapentaenoic/docosahexaenoic PUFA supplements
Study: 14638581
Drug: Fluoxetine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 20 mg/day
Study: 10975513
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/m2 per day for 7 days)
Study: 8470851
Drug: Beclomethasone dipropionate,
Normalized name: Beclomethasone Dipropionate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate, 400 micrograms two times daily during years 3 and 4
Study: 8470851
Drug: Bronchodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator therapy (salbutamol, 400 micrograms, or ipratropium bromide, 40 micrograms) during the first 2 years
Study: 29777534
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment provided by a dentist four to five times a week, in addition to routine oral hygiene.
Study: 24398115
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment
Study: 26864095
Drug: Doublebase Dayleve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublebase Dayleve gel (DELP)
Study: 2756353
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg b.i.d. iv. for two days, followed by oral administration with 750 mg b.i.d. for a total of 14 days
Study: 2756353
Drug: Doxycycline plus
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline plus metronidazole according to a similar scheme of administration
Study: 324570
Drug: Cytotoxic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic treatment (premenopausal women)
Study: 29920688
Drug: Modified Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Constraint-Induced Movement Therapy (mCIMT)
Study: 25910378
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 1 mg/kg/day, amoxicillin 50 mg/kg/day, clarithromycin 14 mg/kg/day for 14 days)
Study: 21122499
Drug: Budesonide-MMX(R) 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-MMX(R) 9 mg tablets
Study: 16168062
Drug: formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol 12 microg twice daily
Study: 10087413
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral methotrexate followed by 800 micrograms vaginal misoprostol 7 days later
Study: 7587919
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (administered 3 or 4 times a day)
Study: 27771133
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for the Treatment of Emotional Disorders in Adolescents (UP‐A)
Study: 23292538
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone valerate cream
Study: 29194749
Drug: Teriparatide (TPTD)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (TPTD) 20 μg/d by subcutaneous injection
Study: 29194749
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid (ZOL) 5 mg/yr by intravenous infusion
Study: 25630243
Drug: Glucosamine-sulfate (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine-sulfate (1000 mg daily, for 8 weeks)
Study: 2051379
Drug: Fixed partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed partial dentures with periodontal therapy
Study: 31004378
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice containing 520 mg nitrate
Study: 31004378
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice containing 520 mg nitrate and 6 g citrulline
Study: 31004378
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice containing 520 mg nitrate and 6 g arginine
Study: 11277826
Drug: Gavestinel (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gavestinel (800 mg loading dose + 200 mg every 12 hours for 3 days), n = 701
Study: 28029656
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low LWR and high MWR
Study: 24050519
Drug: Total delay
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total delay from symptom onset until treatment initiation
Study: 19036082
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg daily plus pulsed dexamethasone 20 mg 4 days a month
Study: 19036082
Drug: Interferon-alpha 3
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 3 MU 3 times a week plus pulsed dexamethasone 20 mg 4 days a month